ZEAL — Zealand Pharma A/S Balance Sheet
0.000.00%
- DKK34.64bn
- DKK18.87bn
- DKK62.69m
- 66
- 81
- 34
- 67
Annual balance sheet for Zealand Pharma A/S, fiscal year end - December 31st, DKK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | — | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 1,258 | 1,428 | 1,178 | 1,633 | 8,226 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 61.9 | 110 | 82.8 | 111 | 176 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 1,420 | 1,722 | 1,316 | 1,780 | 8,528 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 213 | 221 | 165 | 150 | 125 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 1,762 | 2,068 | 1,540 | 1,980 | 9,506 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 355 | 334 | 195 | 285 | 403 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 533 | 1,140 | 724 | 387 | 889 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 1,229 | 928 | 816 | 1,593 | 8,617 |
| Total Liabilities & Shareholders' Equity | 1,762 | 2,068 | 1,540 | 1,980 | 9,506 |
| Total Common Shares Outstanding |